Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
NCT ID: NCT00230763
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
396 participants
INTERVENTIONAL
2005-09-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
NCT00856622
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
NCT00159653
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
NCT00219596
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
NCT00647101
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
in the evening during 84 days
Procedure
GSS questionnaire
D0, D30 and D84
IOP
D0, D30 and D84
Visual acuity
D0 and D84
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSS questionnaire
D0, D30 and D84
IOP
D0, D30 and D84
LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
in the evening during 84 days
Visual acuity
D0 and D84
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged \> than equal to 18 years,
* Patient presenting with an OHT or OAG with an IOP � 21 mmHg,
* Patient currently treated with ophthalmic beta-blockers monotherapy and requiring a change of the ophthalmic medication due to insufficient response to treatment,
Exclusion Criteria
* Patient presenting any contraindication to latanoprost or timolol,
* Patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia (pulse rate \< 60 bpm), auriculo-ventricular block, cardiac insufficiency, Raynaud disease or any other condition that would preclude the patient from taking the prescribed medication,
* Patient with known intolerance to benzalkonium chloride or any excipient contained in the trial treatment,
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Agen, , France
Pfizer Investigational Site
Amboise, , France
Pfizer Investigational Site
Amiens, , France
Pfizer Investigational Site
Andrésy, , France
Pfizer Investigational Site
Asnières-sur-Seine, , France
Pfizer Investigational Site
Aubière, , France
Pfizer Investigational Site
Aurillac, , France
Pfizer Investigational Site
Belfort, , France
Pfizer Investigational Site
Besançon, , France
Pfizer Investigational Site
Béziers, , France
Pfizer Investigational Site
Bordeaux, , France
Pfizer Investigational Site
Bourg-en-Bresse, , France
Pfizer Investigational Site
Caen, , France
Pfizer Investigational Site
Cannes, , France
Pfizer Investigational Site
Castelsarrasin, , France
Pfizer Investigational Site
Chalon-sur-Saône, , France
Pfizer Investigational Site
Chamalieres-Royat, , France
Pfizer Investigational Site
Chambéry, , France
Pfizer Investigational Site
Chartres, , France
Pfizer Investigational Site
Chassieu, , France
Pfizer Investigational Site
Châlons-en-Champagne, , France
Pfizer Investigational Site
Château-Renault, , France
Pfizer Investigational Site
Châteaudun, , France
Pfizer Investigational Site
Clamart, , France
Pfizer Investigational Site
Clermont-Ferrand, , France
Pfizer Investigational Site
Clermont-Ferrand, , France
Pfizer Investigational Site
Colmar, , France
Pfizer Investigational Site
Coulommiers, , France
Pfizer Investigational Site
Dax, , France
Pfizer Investigational Site
Étampes, , France
Pfizer Investigational Site
Figeac, , France
Pfizer Investigational Site
Fréjus, , France
Pfizer Investigational Site
Goussainville, , France
Pfizer Investigational Site
Haguenau, , France
Pfizer Investigational Site
Hyères, , France
Pfizer Investigational Site
Issy-les-Moulineaux, , France
Pfizer Investigational Site
Ivry-sur-Seine, , France
Pfizer Investigational Site
Jarny, , France
Pfizer Investigational Site
La Flèche, , France
Pfizer Investigational Site
Langon, , France
Pfizer Investigational Site
Lannion, , France
Pfizer Investigational Site
Le Mans, , France
Pfizer Investigational Site
Le Quesnoy, , France
Pfizer Investigational Site
Les Clayes-sous-Bois, , France
Pfizer Investigational Site
Les Lilas, , France
Pfizer Investigational Site
Lille, , France
Pfizer Investigational Site
Limoges, , France
Pfizer Investigational Site
Luxeuil-les-Bains, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Meaux, , France
Pfizer Investigational Site
Meudon, , France
Pfizer Investigational Site
Meyzieu, , France
Pfizer Investigational Site
Montargis, , France
Pfizer Investigational Site
Montbéliard, , France
Pfizer Investigational Site
Montigny-le-Bretonneux, , France
Pfizer Investigational Site
Moulins, , France
Pfizer Investigational Site
Mulhouse, , France
Pfizer Investigational Site
Nantes, , France
Pfizer Investigational Site
Nemours, , France
Pfizer Investigational Site
Nice, , France
Pfizer Investigational Site
Nœux-les-Mines, , France
Pfizer Investigational Site
Orléans, , France
Pfizer Investigational Site
Orsay, , France
Pfizer Investigational Site
Pantin, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Pau, , France
Pfizer Investigational Site
Perpignan, , France
Pfizer Investigational Site
Poissy, , France
Pfizer Investigational Site
Quetigny, , France
Pfizer Investigational Site
Rillieux-la-Pape, , France
Pfizer Investigational Site
Roanne, , France
Pfizer Investigational Site
Roquebrune-Cap-Martin, , France
Pfizer Investigational Site
Roye, , France
Pfizer Investigational Site
Saint-Girons, , France
Pfizer Investigational Site
Saint-Laurent-du-Var, , France
Pfizer Investigational Site
Saint-Maur-des-Fossés, , France
Pfizer Investigational Site
Saint-Quentin, , France
Pfizer Investigational Site
Sainte-Maure-de-Touraine, , France
Pfizer Investigational Site
Saintes, , France
Pfizer Investigational Site
Salon-de-Provence, , France
Pfizer Investigational Site
Sceaux, , France
Pfizer Investigational Site
Toulon, , France
Pfizer Investigational Site
Toulouse, , France
Pfizer Investigational Site
Tremblay-en-France, , France
Pfizer Investigational Site
Troyes, , France
Pfizer Investigational Site
Vauvert, , France
Pfizer Investigational Site
Vendôme, , France
Pfizer Investigational Site
Versailles, , France
Pfizer Investigational Site
Viarmes, , France
Pfizer Investigational Site
Villeneuve-la-Garenne, , France
Pfizer Investigational Site
Villeparisis, , France
Pfizer Investigational Site
Villiers-le-Bel, , France
Pfizer Investigational Site
Wasselonne, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sellem E, Rouland JF, Baudouin C, Bron A, Denis P, Nordmann JP, Renard JP. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmol. 2010 Mar 26;10:10. doi: 10.1186/1471-2415-10-10.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6641040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.